tiprankstipranks
Mirum Pharmaceuticals (MIRM)
NASDAQ:MIRM
US Market
MIRM
Mirum Pharmaceuticals
RESEARCH TOOLSreports
Want to see MIRM full AI Analyst Report?

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

769 Followers
See the Price Targets and Ratings of:

MIRM Analyst Ratings

Strong Buy
14Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Mirum
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$145.36
▲(48.40% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $145.36 with a high forecast of $185.00 and a low forecast of $115.00. The average price target represents a 48.40% change from the last price of $97.95.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"$44","115":"$115","186":"$186","79.5":"$79.5","150.5":"$150.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":145.35714285714286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$145.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,79.5,115,150.5,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.33,103.15076923076923,109.97153846153846,116.79230769230769,123.61307692307692,130.43384615384616,137.2546153846154,144.07538461538462,150.89615384615385,157.71692307692308,164.5376923076923,171.35846153846154,178.17923076923077,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.33,100.10131868131867,103.87263736263736,107.64395604395604,111.41527472527473,115.1865934065934,118.95791208791209,122.72923076923077,126.50054945054946,130.27186813186813,134.04318681318682,137.8145054945055,141.58582417582417,{"y":145.35714285714286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.33,97.76615384615384,99.20230769230768,100.63846153846154,102.07461538461538,103.51076923076923,104.94692307692307,106.38307692307693,107.81923076923077,109.25538461538461,110.69153846153846,112.12769230769231,113.56384615384616,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.33,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$185.00Average Price Target$145.36Lowest Price Target$115.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on MIRM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$140→$146
Buy
49.06%
Upside
Reiterated
06/15/26
Mirum Pharmaceuticals price target raised to $146 from $140 at CitizensMirum Pharmaceuticals price target raised to $146 from $140 at Citizens
H.C. Wainwright Analyst forecast on MIRM
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$185
Buy
88.87%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)
Morgan Stanley Analyst forecast on MIRM
Michael Ulz
Morgan Stanley
Morgan Stanley
$150
Buy
53.14%
Upside
Reiterated
06/15/26
Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target
Citi Analyst forecast on MIRM
Yigal Nochomovitz
Citi
Citi
$145
Buy
48.03%
Upside
Reiterated
06/14/26
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
J.P. Morgan Analyst forecast on MIRM
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$115
Buy
17.41%
Upside
Initiated
05/20/26
Mirum Pharmaceuticals (MIRM) Gets a Buy from J.P. Morgan
Wolfe Research Analyst forecast on MIRM
Kalpit Patel
Wolfe Research
Wolfe Research
$145
Buy
48.03%
Upside
Initiated
05/19/26
Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on MIRM
Mani Foroohar
Leerink Partners
Leerink Partners
$150→$154
Buy
57.22%
Upside
Reiterated
05/15/26
Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)
Evercore ISI Analyst forecast on MIRM
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$135→$138
Buy
40.89%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
TD Cowen Analyst forecast on MIRM
Joseph Thome
TD Cowen
TD Cowen
$125→$145
Buy
48.03%
Upside
Assigned
05/07/26
Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)
Raymond James Analyst forecast on MIRM
Ryan Deschner
Raymond James
Raymond James
$164→$165
Buy
68.45%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Stifel Nicolaus Analyst forecast on MIRM
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$130→$136
Buy
38.85%
Upside
Reiterated
05/07/26
Stifel Nicolaus Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
RBC Capital Analyst forecast on MIRM
Lisa Walter
RBC Capital
RBC Capital
$142
Buy
44.97%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on MIRM
Brian Skorney
Robert W. Baird
Robert W. Baird
$112→$129
Buy
31.70%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $129 from $112 at BairdMirum Pharmaceuticals price target raised to $129 from $112 at Baird
Cantor Fitzgerald Analyst forecast on MIRM
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$140
Buy
42.93%
Upside
Reiterated
04/09/26
Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on MIRM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$140→$146
Buy
49.06%
Upside
Reiterated
06/15/26
Mirum Pharmaceuticals price target raised to $146 from $140 at CitizensMirum Pharmaceuticals price target raised to $146 from $140 at Citizens
H.C. Wainwright Analyst forecast on MIRM
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$185
Buy
88.87%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)
Morgan Stanley Analyst forecast on MIRM
Michael Ulz
Morgan Stanley
Morgan Stanley
$150
Buy
53.14%
Upside
Reiterated
06/15/26
Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target
Citi Analyst forecast on MIRM
Yigal Nochomovitz
Citi
Citi
$145
Buy
48.03%
Upside
Reiterated
06/14/26
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
J.P. Morgan Analyst forecast on MIRM
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$115
Buy
17.41%
Upside
Initiated
05/20/26
Mirum Pharmaceuticals (MIRM) Gets a Buy from J.P. Morgan
Wolfe Research Analyst forecast on MIRM
Kalpit Patel
Wolfe Research
Wolfe Research
$145
Buy
48.03%
Upside
Initiated
05/19/26
Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on MIRM
Mani Foroohar
Leerink Partners
Leerink Partners
$150→$154
Buy
57.22%
Upside
Reiterated
05/15/26
Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)
Evercore ISI Analyst forecast on MIRM
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$135→$138
Buy
40.89%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
TD Cowen Analyst forecast on MIRM
Joseph Thome
TD Cowen
TD Cowen
$125→$145
Buy
48.03%
Upside
Assigned
05/07/26
Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)
Raymond James Analyst forecast on MIRM
Ryan Deschner
Raymond James
Raymond James
$164→$165
Buy
68.45%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Stifel Nicolaus Analyst forecast on MIRM
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$130→$136
Buy
38.85%
Upside
Reiterated
05/07/26
Stifel Nicolaus Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
RBC Capital Analyst forecast on MIRM
Lisa Walter
RBC Capital
RBC Capital
$142
Buy
44.97%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on MIRM
Brian Skorney
Robert W. Baird
Robert W. Baird
$112→$129
Buy
31.70%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $129 from $112 at BairdMirum Pharmaceuticals price target raised to $129 from $112 at Baird
Cantor Fitzgerald Analyst forecast on MIRM
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$140
Buy
42.93%
Upside
Reiterated
04/09/26
Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

3 Months
Michael UlzMorgan Stanley
Success Rate
15/19 ratings generated profit
79%
Average Return
+16.57%
Copying Michael Ulz's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +16.57% per trade.
1 Year
Gavin Clark-GartnerEvercore ISI
Success Rate
16/16 ratings generated profit
100%
Average Return
+70.31%
Copying Gavin Clark-Gartner's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +70.31% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
22/22 ratings generated profit
100%
Average Return
+155.93%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +155.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
3
0
1
9
13
Buy
22
21
18
19
17
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
21
19
28
30
In the current month, MIRM has received 30 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 145.36.
Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.74 with a range of -$1.47 to -$0.41. The previous quarter’s EPS was -$13.43. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.
Next quarter’s earnings estimate for MIRM is -$0.74 with a range of -$1.47 to -$0.41. The previous quarter’s EPS was -$13.43. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $166.04M with a range of $160.18M to $173.02M. The previous quarter’s sales results were $159.88M. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.
Next quarter’s sales forecast for MIRM is $166.04M with a range of $160.18M to $173.02M. The previous quarter’s sales results were $159.88M. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirum Pharmaceuticals’s 12-month average price target is 145.36.
    What is MIRM’s upside potential, based on the analysts’ average price target?
    Mirum Pharmaceuticals has 48.40% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MIRM a Buy, Sell or Hold?
          Mirum Pharmaceuticals has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Mirum Pharmaceuticals’s price target?
            The average price target for Mirum Pharmaceuticals is 145.36. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $185.00 ,the lowest forecast is $115.00. The average price target represents 48.40% Increase from the current price of $97.95.
              What do analysts say about Mirum Pharmaceuticals?
              Mirum Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of MIRM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.